IMVT Price Prediction Next Week
Analysis and Insights
News Impact Analysis:
Immunovant (IMVT) recently announced Phase 3 trial results for batoclimab, which met primary endpoints but will not seek regulatory approval until further data is available. This has led to a 14% decline in stock price, reflecting investor concerns about delayed approvals and the company's strategic focus on IMVT-1402 instead of batoclimab.
Technical Analysis:
- RSI: 47.52, indicating a neutral position but near oversold territory.
- MACD: Slightly negative, suggesting bearish momentum.
- Bollinger Bands: Stock price near the lower band, indicating potential undervaluation.
- Fibonacci Levels: Pivot at $19.05, with support at $17.64 and resistance at $20.46.
Options Sentiment:
Selling a January 2026 put at $15 offers a 15.1% annualized return, suggesting some investor confidence in the stock's potential rebound.
Price Prediction:
Based on technical indicators and news sentiment, IMVT is expected to trade between $17.64 and $20.46 next week. The stock is near a support level, and while there's downward pressure from the news, the options market indicates potential for a rebound.
Recommendation:
Buy at the current price of $19.26, targeting a rebound towards the resistance level of $20.46.
IMVT Similar Chart Price Prediction
The price of IMVT is predicted to go up -3.54%, based on the high correlation periods with KOP. The similarity of these two price pattern on the periods is 92.57%.
IMVT
KOP
Down: -3.54%Similarity: 92.57%
IMVT Revenue Forecast
IMVT EPS Forecast
IMVT FAQs
What is IMVT eps forecast for next quarter？
IMVT Analyst's Forecast
Yatin Suneja
Guggenheim
Strong Buy
2025-02-10
Price Target
$46 → $44
Upside
+125.41%
Guggenheim lowered the firm's price target on Immunovant to $44 from $46 and keeps a Buy rating on the shares after having hosted management for an investors lunch and discussed expectations for the upcoming batoclimab readouts, as well as the company's development strategy for their next-gen potentially best-in-class anti-FcRn '1402. The firm has updated its model for fiscal Q3, the analyst noted.
Jason Gerberry
B of A Securities
Strong Buy
2025-01-15
Price Target
$48 → $45
Upside
+84.43%
Andy Chen
Wolfe Research
Buy → Hold
2025-01-03
Price Target
n/a
Downside
0%
